ABOUT DDPDGENES

DDPDGENES is a Collaborative project funded by the European Commission under the 7th Framework Programme and is composed of 4 strong academic groups and 1 biotechnology company from 4 different European countries: Sweden, UK, Switzerland and Spain.

The DDPDGENES project started January 2012 and finalized in December 2015.   

PAST EVENTS

04/11/2015 Join us at the Parkinson's Open Day at Inbiomed in Donostia. Please visit our Facebook page (link below) for fotoreports on past events.

 

01/11/2015 DDPDGENES Fall Meeting to be celebrated in Donostia.

 

27/03/2015 Reserve this date and join us at the Parkinson's Open Day in Barcelona. 

 

25/03/2015 DDPDGENES Spring Meeting to be celebrated in Barcelona

 

22/03/2014 Join us at the Parkinson's Open Day at the John van Geest Centre for Brain Repair (in Cambridge). Read more in the Event's section

 

5/11/2013 Dr. Sten Linnarsson will be guest lecturer at the OUS-Rikshospitalet, Seminar room A3.3067 in Oslo, Norway.

 

10/12/2013 Dr. Roger Barker will speak at the XX World Congress on Parkinson Disease and related disorders in Geneva, Switzerland.

    

DDPDGENES IN THE SOCIAL NETWORKS

PARKINSON DISEASE

Cause

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases and is characterized by three classical symptoms: resting tremor, rigidity and hypokynesia; that progress to additional motor disturbances in gait and balance.

 

At a pathological level, PD is characterized by a progressive loss of dopaminergic neurons in the substantianigra. While these neurons are not believed to be the only cause of the disease, it is their loss that gives rise to the main motor symptoms. Familiar PD, which mostly involves mutations in a gene called LRKK2, accounts for a small portion of the cases, but in the large majority of cases the cause of PD is unknown and termed sporadic.

 

Several studies have suggested that abnormally increased oxidative stress, mitochondrial dysfunction, protein misfoldingand problems in protein degradation are involved, but thorough understanding is missing.

TREATMENT

Treatment of PD is mostly symptomatic. The dying dopaminergic neurons of the sustancianigrado not provide other cells in the brain with dopamine anymore, so patients are administered a dopamine precursor which compensates for the deficit. This mitigates the symptoms of the disease, but doesn’t halt the progression of neurodegeneration.

 

Developmental genes are well known for their ability to regulate multiple aspects of embryogenesis. However, some of these genes have been recently found to serve critical functions in the maintenance of the adult nervous system.

 

The DDPDGENES consortium explores the hypothesis that adult onset PD may involve a dysregulation of the expression of developmental genes involved in the specification of DA neuron subtypes and their interaction with PD-associated genes.